Precision BioSciences, Inc. (DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform, today announced the closing of its in vivo gene editing research collaboration and exclusive license agreement with Eli Lilly and Company following clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.
Seqens CDMO North America, a pharmaceutical manufacturer of new chemical entities, active pharmaceutical ingredients, and other specialty chemical products, issued its annual list of trends that will affect the emerging pharmaceutical and generic drug sectors, as well as Contract Development and Manufacturing Organizations, in 2021.
News, commentary and research reports are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.
PDF’s require Adobe® Reader® and will open in a new window.
